Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

BACKGROUND: Clinically validated prognostic models for overall survival (OS) do not exist for patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) on targeted therapies. A prognostic model is needed to identify high risk individuals not adequately served by available targeted therap...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Haematol
Main Authors: Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6620111/
https://ncbi.nlm.nih.gov/pubmed/31109827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(19)30085-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items